Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Johnson & Johnson offers an annual dividend yield of 3.01%. How can investors exploit its dividend yield to pocket a regula...
The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA® showed highly statist...
The FDA is investigating concerns about metals in tampons after a 2024 study. The agency is conducting an internal study and re...
Johnson & Johnson is facing a lawsuit from Associated Production Music for allegedly using unlicensed music in nearly 80 vi...
Johnson & Johnson announced promising Phase 2 SKIPPirr study results for Rybrevant in reducing infusion-related reactions i...
The study, which included 40 patients, showed that prophylaxis with 8-mg dexamethasone taken for two days prior to the first in...
- Reuters
Truist Securities has initiated coverage on Protagonist Therapeutics, praising its first-in-class lead asset with promising Pha...
Kenvue Inc., owner of major brands like Tylenol, is poised for a technical knockout with a Golden Cross pattern and legal win.
